Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. - Wikidata - thesis-toulmin - TriplyDB

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

http://www.wikidata.org/entity/Q34558111

about

Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA A comparison of different antibiotic regimens for the treatment of infective endocarditis Antibiotics for bacteraemia due to Staphylococcus aureus Antibiotic therapy for treatment of infective endocarditis Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adults Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications Combinatorial biosynthesis of novel antibiotics related to daptomycin Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections Improving Clinical Outcomes in Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin Allergy Progress toward a Staphylococcus aureus vaccine Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria Novel formulations for antimicrobial peptides Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials Daptomycin in paediatrics: current knowledge and the need for future research Methicillin-resistant Staphylococcus aureus therapy: past, present, and future Treatment of Gram-positive infections in critically ill patients Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus Novel antibody-antibiotic conjugate eliminates intracellular S. aureus Bacterial genome engineering and synthetic biology: combating pathogens Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus Managing infective endocarditis in the elderly: new issues for an old disease.Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.Genotypically different clones of Staphylococcus aureus are diverse in the antimicrobial susceptibility patterns and biofilm formations.Management of community-associated methicillin-resistant Staphylococcus aureus infections in children.Safety profiles of old and new antimicrobials for the treatment of MRSA infections.Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options.Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Daptomycin for methicillin-resistant Staphylococcus epidermidis native-valve endocarditis: a case report.A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.Incidence, risk factors and prediction of post-operative acute kidney injury following cardiac surgery for active infective endocarditis: an observational study.Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.Effectiveness and safety of daptomycin in patients with infective endocarditis undergoing heart valve replacement: a subgroup analysis from real-world data.The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials.Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial.A potential role for daptomycin in enterococcal infections: what is the evidence?Waves of resistance: Staphylococcus aureus in the antibiotic era.

P2860

Q22305769-9D3D5F3C-78B9-4979-91CF-F1E7439BC009 Q24185887-23884EF8-DE7F-4E1E-947B-050AB1A7720F Q24186950-B7FF382F-A624-4844-A67D-F04FD727D206 Q24198788-EA0B4C67-9E9E-46F8-AFD4-F869D665715B Q24242508-6E879582-B1F4-4501-A682-8AC98F6A252E Q24614464-CBED8D3D-5206-40BB-83D9-F1F2BB1EB3DF Q24646677-BD1B43BB-054F-4CC1-ABAE-237C3674345F Q24676630-2C511B00-F809-4DB5-8ED8-A8EA2E704AD7 Q24682375-AEF55B2F-780D-4CC2-9FE9-33181A8C6186 Q26752922-B4620EC8-2C54-4AEE-9DB4-B60A25EA1736 Q26779453-2485C934-6D82-458D-9492-482D1D1AD912 Q26829702-9786A960-A7A1-4264-AE69-2E597E87901A Q26853465-4987C917-916D-4C4C-BD07-510DD97E89A0 Q26863225-B2C92FFA-8DEC-44C1-B4AF-02209DDEABDB Q26991771-97F397BE-36B1-4098-8F88-167142F895AC Q27000445-D68AF146-61C8-4213-B8B1-0E0EB7594417 Q27006038-8D07B305-E876-42C3-B88C-961302D01D81 Q27011165-A29C7E5D-6889-4B8F-B888-7132EA4A4191 Q27015976-E93D3EC8-628F-4E36-9F69-D1E62F09A918 Q27027412-CEB70F34-6C3F-49AE-999A-0FAAAC368868 Q27702570-1F63D5C6-934A-4D4A-9EB1-41FCB5F68EF7 Q28066540-D32C11EF-6CFD-4EC5-8183-46E5A0B5E902 Q28740293-2CD6DEA1-9253-495B-B175-FD16471E426C Q30245399-8B9A3F15-3F4A-481F-B8C8-0DF076503661 Q30449846-47B1F3D1-2AA3-44CC-B062-948D432272E1 Q31148610-A36F91C9-B685-4013-88AE-C1DEE5BDFAD7 Q33264579-7B22640E-AF00-4675-A3A3-97826A7F2364 Q33429168-6E31D00D-16CA-4497-A03E-FAA31321B0BF Q33460707-DF130553-3344-416B-9F4B-BE6697411CD7 Q33617737-1FF37852-8BF6-419A-996B-F45C03A97CD2 Q33657212-2452FE20-88C8-4247-B7C3-82844A6E3FBE Q33718381-B9DE8723-E21B-4FCC-9D03-84BA1C6608B1 Q33723124-8454D02A-3CE8-448D-9F16-93FBB37C6F19 Q33752838-E40EF9A7-52FD-4901-9E64-2D6381BBA546 Q33768851-45398EB4-6C44-4435-8179-5E55DBFBAD87 Q33788313-FF4D0FE1-FAA5-4E50-BA50-207F7B125A94 Q33834856-3F07E150-15E7-4BA2-9669-97640C3DC1B4 Q33844670-27C3C2F0-E7EE-41A5-83BB-A444EAFE291F Q33845776-5E5F356C-9EBB-4D1D-94FD-C054204AAA91 Q33854398-332017C4-0435-44DA-A78F-BAAD93076D32

P2860

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

http://www.wikidata.org/entity/Q34558111

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Daptomycin versus standard the ...... used by Staphylococcus aureus.

@ast

Daptomycin versus standard the ...... used by Staphylococcus aureus.

@en

Daptomycin versus standard the ...... used by Staphylococcus aureus.

@nl

type

label

Daptomycin versus standard the ...... used by Staphylococcus aureus.

@ast

Daptomycin versus standard the ...... used by Staphylococcus aureus.

@en

Daptomycin versus standard the ...... used by Staphylococcus aureus.

@nl

prefLabel

Daptomycin versus standard the ...... used by Staphylococcus aureus.

@ast

Daptomycin versus standard the ...... used by Staphylococcus aureus.

@en

Daptomycin versus standard the ...... used by Staphylococcus aureus.

@nl

P1433

Q34558111-DB517751-F1EE-42C6-A83C-75D0595CEB20

P1476

Q34558111-275EA1A7-36AD-475A-A495-2C1796589669

P2093

Q34558111-02E9FAE7-73FC-4B08-9D1A-E9728EB19FF5

Q34558111-1845F87E-9CC9-42FC-95F6-4748D1D3DD9D

Q34558111-1F83C0B7-FC13-485B-A06A-9CDCCD56FA78

Q34558111-328C46FB-9528-4EA1-A3B2-6363705D248C

Q34558111-3ED64008-AA07-4510-92FA-B377FD00F1DB

Q34558111-45622D7A-459C-42F4-B6D7-4D4F6844426D

Q34558111-4805AC35-948F-46AD-AF00-21C4100710DF

Q34558111-49C29781-5817-415B-9FCA-64A841C1BFBD

Q34558111-4D036758-BEED-40F8-9406-74C5F0A971DC

Q34558111-66D79BDD-4FD4-42FE-A6A3-2BC25C6FAC32

P304

Q34558111-12FF55CD-1D58-45E0-8DA7-20337CD3A5BF

P31

Q34558111-5D44B1A4-FF76-43BB-AED6-7EB49814B131

P356

Q34558111-18A35D4C-050A-4923-8626-5FD844767D70

P407

Q34558111-F40360AF-5F1B-4F12-B029-7D5A5E455183

P433

Q34558111-0EF738C6-57A7-4D91-98B3-3B0A147583A9

P478

Q34558111-A8492659-2605-427B-ACFE-C0261976C02F

P50

Q34558111-36729FD8-BC03-4CD6-8223-403F81FF502B

Q34558111-8938A7EF-71FA-4537-BB84-9442ECC72353

P577

Q34558111-9C132993-DBB6-49D2-B767-0557DB29B85E

P698

Q34558111-537413E9-8313-47F8-BB18-B19E7194D2B7

P356

P1433

The New England Journal of Medicine

P1476

Daptomycin versus standard the ...... used by Staphylococcus aureus.

@en

P2093

Adolf W Karchmer

http://www.w3.org/2001/XMLSchema#string

Alan Tice

http://www.w3.org/2001/XMLSchema#string

Arthur Stanley Link

http://www.w3.org/2001/XMLSchema#string

Christopher H Cabell

http://www.w3.org/2001/XMLSchema#string

Connie Savor Price

http://www.w3.org/2001/XMLSchema#string

Donald P Levine

http://www.w3.org/2001/XMLSchema#string

Elias Abrutyn

http://www.w3.org/2001/XMLSchema#string

Francis P Tally

http://www.w3.org/2001/XMLSchema#string

G Ralph Corey

http://www.w3.org/2001/XMLSchema#string

Gloria A Vigliani

http://www.w3.org/2001/XMLSchema#string

P304

653-665

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA053783

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

355

http://www.w3.org/2001/XMLSchema#string

P50

Gerd Fätkenheuer

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16914701

http://www.w3.org/2001/XMLSchema#string